Original Studies

Pimecrolimus for the Treatment of Vulvar Lichen Sclerosus in a Premenarchal Girl

Andrew T. Goldstein, MD, Stanley C. Marinoff, MD, MPH, and Kurt Christopher, MD
1Johns Hopkins School of Medicine, Baltimore, Maryland, USA; 2The George Washington University School of Medicine, Washington, DC, USA; 3Beth Israel Medical Center, New York, New York, USA

Abstract. Background: Lichen sclerosus is a chronic cutaneous disorder with a predilection for the vulva. Lichen sclerosus affects more than one in 900 girls. Superpotent corticosteroids like clobetasol propionate are the most effective treatment for vulvar lichen sclerosus. However, recurrence after stopping steroids is very high. As repeated courses of corticosteroids are frequently needed, there are concerns about potential side effects. Therefore, a treatment regimen that does not rely on corticosteroids may be beneficial. As lichen sclerosus is a T-lymphocyte mediated disorder, it has been suggested that pimecrolimus, a topical T-lymphocyte inhibitor, may be safe and effective for the treatment of lichen sclerosus in children.

Case report: A 10-year-old girl with lichen sclerosus was initially treated with clobetasol. Remission was achieved, but 3 months later she had a recurrence. Subsequent treatment with clobetasol led to a breakdown of her peri-anal skin with a superimposed infection. She was then treated with pimecrolimus and remission was achieved. She has had no recurrence of active lichen sclerosus and has less burning with pimecrolimus than with clobetasol.

Conclusion: Pimecrolimus may be an effective treatment of vulvar lichen sclerosus. Pimecrolimus has been shown to be very safe in the pediatric population for the treatment of mild to moderate eczema, without causing dermal atrophy, tachyphylaxis, striae, rebound flares, or hypothalamic-pituitary axis suppression. As the recurrence rate of active lichen sclerosus in pubertal girls treated with topical corticosteroids is high, and the majority of prepubertal girls with lichen sclerosus continue to have disease after menarche, a treatment regimen that does not rely on corticosteroids may be beneficial.

Key Words. Children—Vulva—Lichen sclerosus—Tacrolimus/analogs & derivatives/therapeutic use

Introduction

Lichen sclerosus is a T-lymphocyte mediated chronic cutaneous disorder with a predilection for the vulva. The prevalence of childhood lichen sclerosus has been estimated to be more than one in 900 girls.1,2 The typical lesions of lichen sclerosus are white plaques, often with areas of ecchymosis, excoriation, and ulceration. Often, there is destruction of vulvar architecture with scarring of the clitoral prepuce, resorption of the labia minora, and narrowing of the introitus. Historically, treatments for lichen sclerosus have included topical estrogens, testosterone, progesterone, retinoids, and oral chloroquine.3-6 In the early 1990s, several well-designed studies demonstrated that clobetasol propionate, a superpotent topical corticosteroid, is the most effective treatment for vulvar lichen sclerosus in adult women.3,4,7,8 Subsequently, there have been three studies examining ultra potent corticosteroids for the treatment of lichen sclerosus in children.9-11 These studies demonstrated the safety and efficacy of superpotent topical corticosteroids in children, but also showed a recurrence rate of up to 82% after stopping steroids.9 In addition, side effects reported in these series include burning, irritation, erythema, and yeast superinfection.9-11 As long-term usage, or repeated courses, of topical corticosteroids are frequently needed, there are concerns about potential side effects. Well-known side effects associated with long-term topical corticosteroid use include: thinning of the dermis, rebound reactions, striae formation, systemic absorption, hypothalamic-pituitary axis suppression, and fungal infections.12-14 In addition, improper use of superpotent corticosteroids can significantly increase the risk of these side effects. Therefore, a treatment regimen that does not rely on corticosteroids may be beneficial for the treatment of childhood lichen sclerosus.

It has been suggested that pimecrolimus, a topical macrolide immunosuppressant, may be safe and efficacious for the treatment of vulvar lichen sclerosus in
children. Pimecrolimus inhibits T-cell activity by inhibiting calcineurin-dependent dephosphorylation-activation of specific nuclear factors, thus preventing transcription of pro-inflammatory cytokines including interleukin 2, 4, 10, and interferon gamma. Pimecrolimus is FDA approved for the treatment of mild to moderate eczema in children 2 years old and greater.

Case Report

A premenarchal 10-year-old girl with a 16-month history of biopsy proven vulvar lichen sclerosis was initially treated with clobetasol ointment 0.05% daily for 3 months. Remission of lichen sclerosus was achieved, but 5 months after cessation of the clobetasol she had a recurrence of active disease. Remission was again achieved with clobetasol, but during this second treatment course she developed breakdown of her perianal skin and had a severe mixed bacterial and yeast infection that was treated with cephalexin and fluconazole. Four months later, she developed a recurrence of active lichen sclerosus (Fig. 1). After a lengthy discussion with the patient and her parents, she was treated with 1% pimecrolimus cream (Elidel, Novartis Pharmaceuticals). She used the pimecrolimus cream twice daily for 3 months and has continued using it every other day for the last 6 months. Remission was achieved within 6 weeks and she has had no recurrence of active lichen sclerosus (Fig. 2). She has had no complications and subjectively has less burning with the pimecrolimus as compared to the clobetasol.

Discussion

In this case, pimecrolimus, a topical macrolide immunosuppresant, was safe and effective in the treatment of vulvar lichen sclerosus. Pimecrolimus has been shown to be very safe in the pediatric population without causing dermal atrophy, tachyphylaxis, striae, rebound flares, vasoconstriction, telangiectasia, or hypothalamic-pituitary axis suppression. Pharmacokinetic studies have shown very low blood levels of pimecrolimus following topical application, with no accumulation after repeated applications. As the recurrence rate of active lichen sclerosus in prepubertal girls treated with topical corticosteroids is high, and recent studies suggest that between 75% and 97% of prepubertal girls with lichen sclerosus continue to have
disease after menarche,\textsuperscript{17,18} a treatment regimen that does not rely on corticosteroids may be beneficial.

Lichen sclerosus is a T-lymphocyte mediated skin disorder. As pimecrolimus inhibits T-lymphocytes, it is plausible that pimecrolimus will prove to be a very effective and safe treatment for lichen sclerosus. Therefore, a randomized trial comparing pimecrolimus and clobetasol should be performed to determine which is the safest and most efficacious in the long-term treatment of lichen sclerosus.

References

7. Dalziel KL, Millard PR, Wojnarowska F: The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124:461